Nontuberculous Mycobacterial Infections Market Summary
- As per DelveInsight, the Nontuberculous Mycobacterial Infections Market Size is expected to expand at a healthy growth rate during the forecast period (2023-2034), owing to the launch of new therapies in the market and the rise in the number of cases.
- The Nontuberculous Mycobacterial Infections companies developing therapies include - Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc., Beyond Air, and others, are actively working in the Nontuberculous Mycobacterial Infections Market.
Request for unlocking the Sample Page of the "Nontuberculous Mycobacterial Infections Market Insights"
Key Factors Driving the Nontuberculous Mycobacterial Infections Market
- Rising Prevalence of NTM Infections: Increasing cases of pulmonary and extrapulmonary NTM infections, especially among immunocompromised individuals, elderly patients, and those with chronic lung diseases like COPD or cystic fibrosis, are driving demand for effective therapies.
- Advancements in Diagnostic Technologies: Improved molecular diagnostic tools, PCR-based assays, and species-specific identification methods are enabling earlier and more accurate detection, which supports timely treatment and expands the market for targeted therapies.
- Emergence of Novel Therapeutics: Development of new drugs, such as ARIKAYCE and investigational agents (e.g., inhaled clofazimine, omadacycline), is enhancing treatment options and improving outcomes for patients with drug-resistant or refractory NTM infections.
- Increasing Awareness Among Clinicians and Patients: Greater awareness of NTM infections, their clinical manifestations, and associated complications has led to improved diagnosis, higher treatment rates, and greater adoption of available therapies globally.
- Supportive Healthcare Infrastructure and Rising Expenditure: Expanding hospital facilities, better access to specialized care, and increased healthcare spending in developed and emerging markets are enabling more patients to receive timely treatment, further fueling market growth.
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Nontuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial Infections therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Nontuberculous Mycobacterial Infections market report provides current treatment practices, emerging drugs, Nontuberculous Mycobacterial Infections market share of the individual therapies, current and forecasted Nontuberculous Mycobacterial Infections market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Nontuberculous Mycobacterial Infections treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nontuberculous Mycobacterial Infections market.
Scope of the Nontuberculous Mycobacterial Infections Market | |
|
Study Period |
2020 to 2034 |
|
Forecast Period |
2024-2034 |
|
Geographies Covered |
|
|
Nontuberculous Mycobacterial Infections Market |
|
|
Nontuberculous Mycobacterial Infections Market Size | |
|
Nontuberculous Mycobacterial Infections Companies |
Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc., Beyond Air, and many others |
|
Nontuberculous Mycobacterial Infections Epidemiology Segmentation |
|
Nontuberculous Mycobacterial Infections Disease Understanding
NTM infections Overview
Non-tuberculous mycobacteria (NTM) are a group of bacteria commonly found in soil, water, and various environmental sources. While not the same as the bacteria that cause tuberculosis (TB), Nontuberculous Mycobacterial Infections can still lead to infections in humans, particularly affecting the lungs but can also involve other parts of the body. These bacteria, which include species like Mycobacterium avium complex (MAC), Mycobacterium abscessus, and Mycobacterium kansasii, can cause opportunistic infections, especially in individuals with weakened immune systems or pre-existing lung conditions. Risk factors for Nontuberculous Mycobacterial Infections infections include chronic lung diseases like bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, prior lung damage, a compromised immune system, and certain genetic predispositions.
NTM infections Signs and Symptoms
The signs and symptoms of Nontuberculous Mycobacterial Infections infections vary depending on the specific bacteria involved and the affected area of the body. Pulmonary Nontuberculous Mycobacterial Infections infections may present with chronic cough, shortness of breath, fatigue, unintentional weight loss, and recurrent respiratory infections. Infections outside the lungs can cause skin lesions, lymph node swelling, joint pain, and even disseminated infections affecting multiple organs in severe cases.
NTM infections Diagnosis
Diagnosing Nontuberculous Mycobacterial Infections infections involves a combination of clinical evaluation, medical history review, imaging studies (such as chest X-rays or CT scans), and laboratory tests. Sputum cultures, bronchoscopy with bronchoalveolar lavage (BAL), and biopsies of affected tissues may be performed to isolate and identify the specific Nontuberculous Mycobacterial Infections species causing the infection.
Treatment Options in the NTM infections
Treating Nontuberculous Mycobacterial Infections infections can be challenging due to the bacteria's resistance to many antibiotics and the need for long-term therapy. Treatment often involves multiple antibiotics taken over an extended period, typically lasting months to years. The specific antibiotics used and the duration of treatment depend on the type of NTM infection, its severity, and the individual's overall health condition. In some cases, surgical intervention may be necessary to remove infected tissue or to manage complications like bronchiectasis.
Nontuberculous Mycobacterial Infections Epidemiology
The Nontuberculous Mycobacterial Infections epidemiology section provides insights into the historical and current Nontuberculous Mycobacterial Infections patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Nontuberculous Mycobacterial Infections market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
NTM infections Epidemiology Key Findings
The Nontuberculous Mycobacterial Infections epidemiology covered in the report provides historical as well as forecasted Nontuberculous Mycobacterial Infections epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise- NTM infections Epidemiology
The epidemiology segment also provides the Nontuberculous Mycobacterial Infections epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
NTM infections Epidemiology Segmentation
- Total Prevalent Cases of NTM Infections in the 7MM
- Total Diagnosed Prevalent Cases of NTM Infections in the 7MM
- Gender-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
- Species-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
- Type-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
- Severity-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
- Treatable Cases of NTM Infections in the 7MM
Recent Developments In The NTM Infections Treatment Landscape
- In January 2025, Shanghai MicuRx Pharmaceutical Co Ltd announced that MRX-5, its anti-infection drug, has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections.
- In November 2024, Paratek Pharmaceuticals released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease.
- In October 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of Phase I clinical trial of MRX-5 in Australia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycobacterial (NTM) infections
Nontuberculous Mycobacterial Infections Drug Analysis
The drug chapter segment of the Nontuberculous Mycobacterial Infections report encloses the detailed analysis of Nontuberculous Mycobacterial Infections marketed drugs and late-stage (Phase-III and Phase-II) Nontuberculous Mycobacterial Infections pipeline drugs. It also helps to understand the Nontuberculous Mycobacterial Infections clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Nontuberculous Mycobacterial Infections Marketed Drugs
The current marketed drug landscape for NTM infections includes both approved therapies and commonly used antibiotics employed in clinical practice to manage NTM disease, particularly pulmonary forms:
- ARIKAYCE (amikacin liposome inhalation suspension): The first and only FDA‑approved targeted therapy for refractory Mycobacterium avium complex (MAC) lung disease in adults as part of a combination regimen. Its inhaled liposomal formulation delivers amikacin directly to the lungs, improving local efficacy while reducing systemic exposure.
- Macrolide Antibiotics: Clarithromycin and azithromycin are key components of standard multidrug antibiotic regimens for MAC and other NTM infections.
- Rifamycins and Rifampin/Rifabutin: These rifamycin‑class agents are frequently used in combination therapy to enhance treatment efficacy against certain NTM species.
- Ethambutol: A bacteriostatic antibiotic commonly included in first‑line multidrug regimens for various NTM infections to help limit bacterial cell wall synthesis.
- Aminoglycosides: Amikacin (beyond ARIKAYCE) and streptomycin are used in combination protocols, especially for more severe or resistant cases.
- Fluoroquinolones and Oxazolidinones: Agents like moxifloxacin, ciprofloxacin, linezolid, and tedizolid may be used off‑label or in combination regimens, particularly for difficult‑to‑treat NTM strains.
Overall, beyond ARIKAYCE’s specific approval, most NTM treatments rely on combination antibiotic regimens tailored to the infecting species and patient response, reflecting the complexity of managing these infections and the ongoing need for more novel therapies.
Nontuberculous Mycobacterial Infections Emerging Drugs
Several novel and investigational therapies are advancing through the development pipeline to address the unmet need in treating NTM infections, especially pulmonary disease caused by Mycobacterium avium complex (MAC) and M. abscessus:
- MNKD‑101 (Clofazimine Inhalation Suspension): A nebulized formulation of clofazimine designed for targeted lung delivery in chronic NTM pulmonary disease. It has received orphan/fast‑track designations and is progressing toward late‑stage studies.
- Omadacycline (Nuzyra): An oral aminomethylcycline antibiotic being evaluated in clinical trials for NTM infections, showing promising results especially against M. abscessus complex.
- Epetraborole: An orally administered investigational agent that inhibits bacterial protein synthesis; currently in Phase II/III development for NTM lung disease.
- MRX‑5: A benzoxazole antibiotic granted FDA Orphan Drug Designation, aimed at expanding therapeutic options for NTM infections.
- Novel Antibiotic Candidates & Repurposed Agents: Compounds like CRS0393, which targets mycobacterial cell‑wall synthesis, and repurposed agents such as bedaquiline (studied beyond TB) reflect broader strategies to enhance efficacy against resistant NTM pathogens.
These emerging drugs represent a shift toward targeted, inhaled, and oral therapies, with many entering mid‑to‑late clinical stages, reflecting significant progress in addressing the challenges of long‑term, multidrug antibiotic regimens historically used for NTM infection treatment.
Nontuberculous Mycobacterial Infections Market Outlook
The Nontuberculous Mycobacterial Infections market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Nontuberculous Mycobacterial Infections market trends by analyzing the impact of current Nontuberculous Mycobacterial Infections therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Nontuberculous Mycobacterial Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Nontuberculous Mycobacterial Infections market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Nontuberculous Mycobacterial Infections market in 7MM is expected to witness a major change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Nontuberculous Mycobacterial Infections market outlook in the 7MM.
The United States Nontuberculous Mycobacterial Infections Market Outlook
This section provides the total Nontuberculous Mycobacterial Infections market size and market size by therapies in the United States.
EU-5 Countries Nontuberculous Mycobacterial Infections Market Outlook
The total Nontuberculous Mycobacterial Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Nontuberculous Mycobacterial Infections Market Outlook
The total Nontuberculous Mycobacterial Infections market size and market size by therapies in Japan is also mentioned.
Nontuberculous Mycobacterial Infections Competitive Landscape
The competitive landscape of the NTM infections market is shaped by established pharmaceutical leaders, specialized biotech firms, and evolving treatment approaches focused on overcoming the challenges of prolonged, multi‑drug therapy and species‑specific infection management. The market currently relies heavily on generic antibiotics and limited approved therapies, but is gradually evolving with more targeted and novel entrants.
- Established Pharma Players: Major pharmaceutical companies such as Insmed Incorporated, Novartis AG, Johnson & Johnson, Pfizer Inc., Sanofi, Teva, and Eli Lilly maintain strong presence through broad antimicrobial portfolios and global distribution networks that support conventional NTM treatment regimens.
- Specialized Biotech Innovators: Biotechnology firms like Spero Therapeutics, AN2 Therapeutics, and Mannkind Corporation are advancing novel therapies and formulations, aiming to address refractory cases and drug‑resistant NTM strains. These innovators often collaborate with research institutions to accelerate development.
- Diagnostic and Treatment Drivers: As precise species identification becomes more critical for effective therapy, competition also encompasses diagnostic improvements that guide targeted treatment strategies and enhance clinical decision‑making.
- Market Dynamics: The landscape features a transition from off‑label broad‑spectrum antibiotic use to more targeted and newer agents in development, with ARIKAYCE currently dominating the approved treatment segment. Emerging pipeline drugs and regulatory incentives such as orphan designations and QIDP status are expected to influence competitive positioning over time.
Key Nontuberculous Mycobacterial Infections Companies
The Key Nontuberculous Mycobacterial Infections companies actively involved in the Nontuberculous Mycobacterial Infections treatment landscape include -
- Insmed Incorporated
- RedHill Biopharma
- Novoteris
- Savara Inc.
- Beyond Air, and others
Nontuberculous Mycobacterial Infections Drugs Uptake
This section focuses on the rate of uptake of the potential Nontuberculous Mycobacterial Infections drugs recently launched in the Nontuberculous Mycobacterial Infections market or expected to get launched in the market during the study period 2020-2034. The analysis covers the Nontuberculous Mycobacterial Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.
Nontuberculous Mycobacterial Infections Drugs Uptake helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs on the basis of Nontuberculous Mycobacterial Infections market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Nontuberculous Mycobacterial Infections Clinical Trial Activities
The Nontuberculous Mycobacterial Infections pipeline report provides insights into different Nontuberculous Mycobacterial Infections clincial trials Phase II, and Phase III stages. It also analyses Nontuberculous Mycobacterial Infections of key players involved in developing targeted therapeutics.
Nontuberculous Mycobacterial Infections Pipeline Development Activities
The Nontuberculous Mycobacterial Infections clinical trials analysis report covers detailed information on collaborations, acquisitions, mergers, licensing, patent details, and other information for Nontuberculous Mycobacterial Infections emerging therapies.
Nontuberculous Mycobacterial Infections Market Growth Factors
The market for Nontuberculous Mycobacterial Infections treatment is influenced by several factors. Ongoing research focused on understanding Nontuberculous Mycobacterial Infections infections, identifying more effective antibiotics, and developing targeted therapies to drive market growth. Technological advancements in diagnostic techniques, such as improved culture methods and molecular testing, contribute to early and accurate diagnosis, expanding the market. Additionally, increased awareness among healthcare professionals about Nontuberculous Mycobacterial Infections infections, efforts to improve access to specialized care, and initiatives to address unmet medical needs in NTM management play a crucial role in advancing the Nontuberculous Mycobacterial Infections treatment market.
Nontuberculous Mycobacterial Infections Market Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Latest KOL- Views on Nontuberculous Mycobacterial Infections Market Report
To keep up with current Nontuberculous Mycobacterial Infections market trends, we take KOLs and SMEs ' opinions working in the Nontuberculous Mycobacterial Infections domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Nontuberculous Mycobacterial Infections market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Nontuberculous Mycobacterial Infections Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Nontuberculous Mycobacterial Infections Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Nontuberculous Mycobacterial Infections Market Report
- The report covers the descriptive overview of Nontuberculous Mycobacterial Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Nontuberculous Mycobacterial Infections epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Nontuberculous Mycobacterial Infections is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Nontuberculous Mycobacterial Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Nontuberculous Mycobacterial Infections market
Nontuberculous Mycobacterial Infections Market Report Highlights
- In the coming years, the Nontuberculous Mycobacterial Infections market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacterial Infections R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Nontuberculous Mycobacterial Infections. The launch of emerging therapies will significantly impact the Nontuberculous Mycobacterial Infections market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Nontuberculous Mycobacterial Infections
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Nontuberculous Mycobacterial Infections Market Report Insights
- Nontuberculous Mycobacterial Infections Patient Population
- Nontuberculous Mycobacterial Infections Therapeutic Approaches
- Nontuberculous Mycobacterial Infections Pipeline Analysis
- Nontuberculous Mycobacterial Infections Market Size and Trends
- Nontuberculous Mycobacterial Infections Market Opportunities
- Impact of upcoming Nontuberculous Mycobacterial Infections Therapies
- Nontuberculous Mycobacterial Infections Drugs Market
Nontuberculous Mycobacterial Infections Market Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Nontuberculous Mycobacterial Infections Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Nontuberculous Mycobacterial Infections Drugs Uptake
Nontuberculous Mycobacterial Infections Report Assessment
- Current Nontuberculous Mycobacterial Infections Treatment Practices
- Nontuberculous Mycobacterial Infections Unmet Needs
- Nontuberculous Mycobacterial Infections Pipeline Product Profiles
- Nontuberculous Mycobacterial Infections Market Attractiveness
- Nontuberculous Mycobacterial Infections Market Drivers
- Nontuberculous Mycobacterial Infections Market Barriers
Key Questions Answered In The Nontuberculous Mycobacterial Infections Market Report:
Nontuberculous Mycobacterial Infections Market Insights:
- What was the Nontuberculous Mycobacterial Infections drug class share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Nontuberculous Mycobacterial Infections total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Nontuberculous Mycobacterial Infections market size during the forecast period (2020-2034)?
- At what CAGR, the Nontuberculous Mycobacterial Infections market is expected to grow by 7MM during the forecast period (2020-2034)?
- What would be the Nontuberculous Mycobacterial Infections market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Nontuberculous Mycobacterial Infections market growth till 2034, and what will be the resultant market Size in the year 2034?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Nontuberculous Mycobacterial Infections Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Nontuberculous Mycobacterial Infections?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Nontuberculous Mycobacterial Infections patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Nontuberculous Mycobacterial Infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Nontuberculous Mycobacterial Infections?
- Out of all 7MM countries, which country would have the highest prevalent population of Nontuberculous Mycobacterial Infections during the forecast period (2020-2034)?
- At what CAGR the patient population is expected to grow to 7MM during the forecast period (2020-2034)?
Current Nontuberculous Mycobacterial Infections Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for the Nontuberculous Mycobacterial Infections treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Nontuberculous Mycobacterial Infections in the USA, Europe, and Japan?
- What are the Nontuberculous Mycobacterial Infections marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Nontuberculous Mycobacterial Infections?
- How many therapies are in development by each company for Nontuberculous Mycobacterial Infections treatment?
- How many are emerging therapies in the mid-stage, and late stage of development for Nontuberculous Mycobacterial Infections treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Nontuberculous Mycobacterial Infections therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
- What are the clinical studies going on for Nontuberculous Mycobacterial Infections and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Nontuberculous Mycobacterial Infections?
- What are the global historical and forecasted market of Nontuberculous Mycobacterial Infections?
Reasons to buy Nontuberculous Mycobacterial Infections Market Forecast Report
- The report will help in developing business strategies by understanding trends shaping and driving the Nontuberculous Mycobacterial Infections market
- To understand the future market competition in the Nontuberculous Mycobacterial Infections market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Nontuberculous Mycobacterial Infections in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Nontuberculous Mycobacterial Infections market
- To understand the future market competition in the Nontuberculous Mycobacterial Infections market
-infections-pipeline.png&w=256&q=75)
